Anocca
Sweden - SödertäljeBiotechnology
Focus: Anocca is a Swedish biotech focused on individualized TCR-modified T cell therapies targeting specific cancer mutations, particularly KRAS variants in pancreatic cancer. The company is in early-stage clinical development with a focused pipeline.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Anocca
AI assessmentNot HiringNo open roles listed right now. Follow Anocca to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
4 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
ANOC-001
PDACClinical Trials (1)
NCT07145450Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC
Phase 1/2Help build intelligence for Anocca
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.